Glaukos Bundle
How did Glaukos redefine glaucoma care?
Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS) with the iStent, shifting treatment from filtration surgeries and lifelong drops to procedure-based, tissue-sparing options integrated into cataract surgery. Founded in 1998 in Laguna Hills, CA, it began to tackle glaucoma’s global burden.
From a venture-backed startup to a diversified ophthalmic platform, Glaukos now markets multiple iStent generations, pursues sustained drug delivery with iDose TR, and expands into corneal and retinal therapies.
What is Brief History of Glaukos Company? Glaukos introduced the first FDA-cleared MIGS device in 2012, transforming surgical glaucoma care and evolving into a medtech and pharma developer focused on minimally invasive procedures and sustained therapies. Glaukos Porter's Five Forces Analysis
What is the Glaukos Founding Story?
Glaukos was founded on January 28, 1998 by ophthalmic entrepreneur Olav B. Bergheim and surgeon-innovators to develop a micro-scale trabecular meshwork bypass implant that reduced morbidity from traditional glaucoma surgery.
Founding Story
Early seed capital, engineering talent and glaucoma surgeons converged in Orange County to build the first trabecular micro-bypass stent and pursue regulatory trials.
- Founded on January 28, 1998 by Olav B. Bergheim and clinical collaborators
- Targeted adherence and side-effect issues from topical drops with a minimally invasive, ab interno implant
- Business model: single-use implant sold through ophthalmic surgical channels and co-implanted during cataract procedures
- Early funding from Domain Associates and healthcare investors; progressed to pivotal FDA trials for the first iStent
Founders marshaled venture rounds and leveraged Orange County's medtech ecosystem of device engineers, contract manufacturers and cataract/glaucoma KOLs to iterate prototypes and build clinical evidence.
Early clinical focus addressed patient non-adherence and high-risk trabeculectomy outcomes by enabling earlier, less invasive intervention with faster recovery, laying the groundwork for Glaukos history and its evolution in minimally invasive glaucoma surgery.
Key early milestones included feasibility studies in the early 2000s, FDA pivotal trials leading to the first iStent approval pathway, and growth toward commercialization channels that combined surgeon training with outcomes data to drive adoption of Glaukos ophthalmic devices.
For deeper context on corporate mission and strategy see Mission, Vision & Core Values of Glaukos
Glaukos SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Glaukos?
Early Growth and Expansion traces how Glaukos scaled from CE Mark clearance in 2009 to U.S. commercialization, IPO funding and product-line diversification that drove rapid revenue and international footprint expansion.
Regulatory and Commercial Breakthroughs
After CE Mark in 2009, the company won FDA approval for the first-generation iStent (GTS100) in 2012 for use with cataract surgery, enabling U.S. commercialization and rapid surgeon adoption that seeded early revenue growth.
Surgeon Education and Market Uptake
Growth was driven by training programs and society presentations showing meaningful intraocular pressure (IOP) reduction and reduced drop burden, accelerating clinician uptake of Glaukos ophthalmic devices.
Infrastructure and Manufacturing Scale
To support volume, the company expanded U.S. sales infrastructure, established distributors internationally, opened additional facilities in San Clemente/Aliso Viejo, CA, and built manufacturing and quality systems aligned with regulatory requirements.
Product Innovation and Pipeline Diversification
FDA clearance for the two-stent iStent inject arrived in 2018 and iStent inject W in 2020, while the sustained-release iDose Travoprost advanced through Phase 3 and gained FDA approval in December 2023, launching in the U.S. in 2024.
Capital markets and competitive response framed expansion: Glaukos completed an IPO on the NYSE (ticker: GKOS) in June 2015, raising growth capital; revenue rose to about $316 million in 2022 and roughly $321 million in 2023, with 2024–2025 growth supported by the iDose TR rollout and ongoing MIGS adoption amid competition from alternative MIGS and goniotomy/canal-based procedures.
Glaukos PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Glaukos history?
Milestones, innovations and challenges in Glaukos history track the company’s path from MIGS category creation to multi-modality glaucoma solutions, highlighting device firsts, drug‑device approvals and commercialization hurdles up to 2025.
| Year | Milestone |
|---|---|
| 2012 | FDA clearance of the iStent, the first MIGS device, establishing Glaukos as a leader in minimally invasive glaucoma surgery. |
| 2018 | Launch of iStent inject, enabling improved micro‑stent placement and broader surgeon adoption within cataract workflows. |
| 2020 | Introduction of iStent inject W, refining lumen geometry and delivery for enhanced efficacy. |
| 2022 | FDA approval of iStent infinite as a standalone option for refractory primary open‑angle glaucoma (POAG). |
| 2023 | FDA approval of iDose TR, the first exchangeable sustained‑release travoprost implant delivering ≥6 months IOP control for many patients. |
Glaukos innovations include the original iStent (2012), iterative device improvements (iStent inject 2018; inject W 2020), a standalone MIGS implant (iStent infinite 2022) and a drug‑device platform (iDose TR 2023) delivering sustained prostaglandin therapy.
First FDA‑cleared MIGS
iStent (2012) created the clinical and commercial category for minimally invasive glaucoma surgery integrated with cataract procedures.
Micro‑stent delivery evolution
iStent inject (2018) and iStent inject W (2020) improved surgeon ergonomics and multi‑stent placement accuracy to raise efficacy rates.
Standalone MIGS for refractory disease
iStent infinite (FDA 2022) provided an option specifically for refractory POAG patients not controlled by prior therapies.
Sustained‑release drug‑device platform
iDose TR (FDA 2023) demonstrated that a single in‑clinic implant can produce clinically meaningful IOP reduction for six months or longer for many patients.
Intellectual property and training
Glaukos assembled a broad IP estate across micro‑implants, delivery systems and drug‑device combos and built surgeon training platforms to institutionalize MIGS in cataract workflows.
Commercial scale‑up
By 2024–2025 Glaukos expanded global commercial footprint, reporting year‑over‑year revenue growth after pandemic disruptions and diversifying beyond a single device franchise.
Challenges for Glaukos included evolving reimbursement for MIGS, competition from other canal‑based and suprachoroidal procedures, lengthy drug‑device regulatory timelines and litigation typical of medtech incumbents.
Reimbursement and adoption
Securing durable reimbursement codes and convincing payors and surgeons of long‑term value required longitudinal outcomes and economic evidence across multiple healthcare systems.
Competitive pressure
Canaloplasty, trabecular bypass variants and non‑implant approaches increased the need for clear clinical differentiation and real‑world effectiveness data.
Regulatory complexity
Developing drug‑device combinations extended timelines and cost, though successful iDose Phase 3 outcomes and 2023 FDA approval validated the strategy.
Pandemic impact and investment
COVID‑19 disrupted elective cataract and MIGS volumes in 2020–2021, yet Glaukos continued R&D spending to preserve innovation cadence and pipeline momentum.
Portfolio diversification
Management broadened strategy from single‑device reliance toward multi‑modality pipelines (device, drug‑device, pharmaceutical) to address glaucoma heterogeneity and reduce franchise risk.
Strategic lessons
Glaukos paired category creation with longitudinal evidence, addressed adherence with procedural and sustained‑delivery solutions, and protected market position via IP and surgeon training.
For a focused review of Go‑to‑Market and clinical positioning strategies, see Marketing Strategy of Glaukos.
Glaukos Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Glaukos?
Timeline and Future Outlook of the Glaukos company overview traces its evolution from a 1998 Laguna Hills startup developing micro-bypass solutions to a diversified ophthalmic device and drug‑delivery firm targeting safer, earlier glaucoma interventions and sustained ocular therapies.
| Year | Key Event |
|---|---|
| 1998 | Founded in Laguna Hills, CA to develop a micro-bypass solution for glaucoma focusing on minimally invasive approaches. |
| 2009 | Received CE Mark for the first‑generation iStent, enabling European commercialization of its MIGS device. |
| 2012 | FDA approved iStent for use with cataract surgery, effectively launching the MIGS era in the U.S. |
| 2015 | Completed IPO on NYSE (GKOS), raising capital to fund global commercialization and R&D expansion. |
| 2018 | FDA approved iStent inject (two stents, ab interno), broadening clinical adoption and efficacy profiles. |
| 2020 | FDA cleared iStent inject W; company reported U.S. and OUS growth despite COVID‑19 headwinds. |
| 2022 | FDA approved iStent infinite for standalone use in refractory open‑angle glaucoma, expanding indications. |
| 2023 | FDA approved iDose TR (travoprost intraocular implant) in December, establishing a drug‑device sustained‑delivery portfolio. |
| 2024 | U.S. launch of iDose TR; MIGS penetration continued and revenue mix began shifting toward sustained‑delivery products. |
| 2024–2025 | Progressed OUS submissions and rollouts for iDose TR; ongoing studies on durability and exchange cycles. |
| 2025+ | Pipeline advances include next‑gen stents, corneal iLink program maturation, and retina sustained‑delivery programs targeting DME and AMD. |
Market penetration and revenue trajectory
With MIGS now standard in many cataract+glaucoma cases and iDose TR launched in 2024, management projects multi‑year double‑digit revenue growth as procedure volumes normalize and new products contribute.
Addressable market expansion
Strategy emphasizes expanding the glaucoma TAM through earlier intervention and standalone indications, leveraging drug‑device combos to improve adherence amid global glaucoma prevalence estimated at 76–80 million.
R&D and pipeline diversification
R&D focuses on next‑gen stents and delivery systems, corneal cross‑linking/iLink maturation, and retina sustained‑delivery candidates for DME and AMD to diversify growth beyond glaucoma.
Commercial and reimbursement strategy
Plans include scaling internationally, generating health‑economic evidence to support reimbursement, and driving manufacturing efficiencies to expand margins as iDose TR scales.
Relevant reading: Competitors Landscape of Glaukos
Glaukos Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of Glaukos Company?
- What is Growth Strategy and Future Prospects of Glaukos Company?
- How Does Glaukos Company Work?
- What is Sales and Marketing Strategy of Glaukos Company?
- What are Mission Vision & Core Values of Glaukos Company?
- Who Owns Glaukos Company?
- What is Customer Demographics and Target Market of Glaukos Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.